Crossmark

Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial

Crossref DOI link: https://doi.org/10.1007/s00345-024-05412-4

Published Online: 2025-01-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Xuyu

Zhou, Feng

Lu, Tong

Zhang, Shun

Wei, Xuedong

Qiu, Xuefeng

Xu, Linfeng

Guo, Hongqian

Zhuang, Junlong
Funding

Funding for this research was provided by:

Natural Science Foundation of Jiangsu Province (BE2020622, BK20200051)

Sino-German Mobility Programme (M-0670)

National Natural Science Foundation of China (81974394)

Nanjing Health Technology Development Project Foundation (JQX23001)

Affiliated Drum Tower Hospital, Medical School of Nanjing University (2022-LCYJ-MS-29)
License Information

Text and Data Mining valid from 2025-01-03

Version of Record valid from 2025-01-03
More Information

Article History

Received: 2 June 2024

Accepted: 6 December 2024

First Online: 3 January 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below